Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00333112 · ClinicalTrials.gov registry record · Phase 4

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

A Phase 4 study of Urinary Incontinence, sponsored by Astellas Pharma.

Completed
Registry status
Phase 4
Development phase
398
Enrollment target
20
Study locations

NCT00333112: Completed Phase 4 study of Urinary Incontinence, sponsored by Astellas Pharma.

NCT00333112 is a Phase 4 study of Urinary Incontinence that has completed, run by Astellas Pharma. The registered enrollment target is 398 participants, above the 254-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00333112, a Phase 4 study of Urinary Incontinence, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 4
Development phase
398 participants
Enrollment target
20
Study locations

Study Summary

A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG solifenacin succinate
  • DRUG tamsulosin

Study Locations (20)

California

  • - Atherton
  • - Beverly Hills
  • - Buena
  • - Buena Park
  • - Carmichael
  • - Culver City
  • - Fresno
  • - Mission Hills
  • - Modesto
  • - Orange
  • - San Bernardino
  • - San Diego
  • - Torrance

Colorado

  • - Aurora
  • - Denver
  • - Wheat Ridge

Arizona

  • - Phoenix
  • - Tuscon

Alabama

  • - Birmingham

Connecticut

  • - Danbury

Trial Details

FieldValue
Enrollment Target 398 participants
Start Date 2006-05
Est. Completion 2007-01
Phase Phase 4
Astellas Pharma

165 total trials

What the finished NCT00333112 record still lists

NCT00333112 is an interventional study that assigns participants to a tested intervention. The registered 398 participants enrollment target is mid-sized for trials with a published cap, above the 254-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (57% higher).

The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00333112 names 20 study sites across 5 states, led by California, Colorado, Arizona.

Frequently Asked Questions

What is clinical trial NCT00333112 about?

NCT00333112 is a clinical study titled "A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.". A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.

What is the current status of trial NCT00333112?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 398 participants. The study started on 2006-05. Estimated completion is 2007-01.

What conditions does trial NCT00333112 study?

This clinical trial studies the following conditions: Urinary Incontinence.

What interventions are being tested in trial NCT00333112?

The interventions under investigation include: placebo (DRUG), solifenacin succinate (DRUG), tamsulosin (DRUG).

Who is sponsoring clinical trial NCT00333112?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00333112 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00333112's enrollment target sits among peer trials

398 10th of 48 higher than 39 of 48 other Urinary Incontinence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05365581 · 398 participants · Phase 1

    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

  • NCT03165734 · 399 participants · Phase 3

    A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  • NCT05022862 · 399 participants · NA

    Economic Incentives and vDOT for Latent Tuberculosis Infection

  • NCT00601939 · 397 participants · NA

    Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00333112, the US trial registry maintained by the National Library of Medicine. NCT00333112 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.